168 related articles for article (PubMed ID: 19072654)
1. Antitumor activity of G3139 lipid nanoparticles (LNPs).
Pan X; Chen L; Liu S; Yang X; Gao JX; Lee RJ
Mol Pharm; 2009; 6(1):211-20. PubMed ID: 19072654
[TBL] [Abstract][Full Text] [Related]
2. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
[TBL] [Abstract][Full Text] [Related]
3. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
[TBL] [Abstract][Full Text] [Related]
5. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
[TBL] [Abstract][Full Text] [Related]
6. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
8. Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles.
Yan C; Gu J; Zhang Y; Ma K; Lee RJ
Int J Pharm; 2022 Sep; 625():122074. PubMed ID: 35932928
[TBL] [Abstract][Full Text] [Related]
9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
10. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
Lopes de Menezes DE; Hu Y; Mayer LD
J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
[TBL] [Abstract][Full Text] [Related]
13. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
[TBL] [Abstract][Full Text] [Related]
14. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA
Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901
[TBL] [Abstract][Full Text] [Related]
15. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
Lacy J; Loomis R; Grill S; Srimatkandada P; Carbone R; Cheng YC
Int J Cancer; 2006 Jul; 119(2):309-16. PubMed ID: 16477627
[TBL] [Abstract][Full Text] [Related]
16. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
[TBL] [Abstract][Full Text] [Related]
17. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
18. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
[TBL] [Abstract][Full Text] [Related]
19. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA
Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Nichols GL; Stein CA
Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
